Literature DB >> 23306770

Where to for pelvic organ prolapse treatment after the FDA pronouncements? A systematic review of the recent literature.

J M van Geelen1, P L Dwyer.   

Abstract

INTRODUCTION: With the publication of the updated US Food and Drug Administration (FDA) communication in 2011 on the use of transvaginal placement of mesh for pelvic organ prolapse (POP) it is appropriate to now review recent studies of good quality on POP to assess the safety and effectiveness of treatment options and determine their place in management.
METHODS: A systematic search for studies on the conservative and surgical management of POP published in the English literature between January 2002 and October 2012 was performed. Studies included were review articles, randomized controlled trials, prospective and relevant retrospective studies as well as conference abstracts. Selected articles were appraised by the authors regarding clinical relevance.
RESULTS: Prospective comparative studies show that vaginal pessaries constitute an effective and safe treatment for POP and should be offered as first treatment of choice in women with symptomatic POP. However, a pessary will have to be used for the patient's lifetime. Abdominal sacral colpopexy is effective in treating apical prolapse with an acceptable benefit-risk ratio. This procedure should be balanced against the low but non-negligible risk of serious complications. The results of native tissue vaginal POP repair are better than previously thought with high patient satisfaction and acceptable reoperation rates. The insertion of mesh at the time of anterior vaginal wall repair reduces the awareness of prolapse as well as the risk of recurrent anterior prolapse. There is no difference in anatomic and subjective outcome when native tissue vaginal repairs are compared with multicompartment vaginal mesh. Mesh exposure is still a significant problem requiring surgical excision in approximately ≥ 10 % of cases. The ideal mesh has not yet been found necessitating more basic research into mesh properties and host response. Several studies indicate that greater surgical experience is correlated with fewer mesh complications. In women with uterovaginal prolapse uterine preservation is a feasible option which women should be offered. Randomized studies with long-term follow-up are advisable to establish the place of uterine preservation in POP surgery.
CONCLUSION: Over the last decade treatment of POP has been dominated by the use of mesh. Conservative treatment is the first option in women with POP. Surgical repair with or without mesh generally results in good short-term objective and functional outcomes. However, basic research into mesh properties with host response and comparative studies with long-term follow-up are urgently needed.

Entities:  

Mesh:

Year:  2013        PMID: 23306770     DOI: 10.1007/s00192-012-2025-3

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  78 in total

1.  Colporrhaphy compared with mesh or graft-reinforced vaginal paravaginal repair for anterior vaginal wall prolapse: a randomized controlled trial.

Authors:  Shawn A Menefee; Keisha Y Dyer; Emily S Lukacz; Amanda J Simsiman; Karl M Luber; John N Nguyen
Journal:  Obstet Gynecol       Date:  2011-12       Impact factor: 7.661

Review 2.  Surgical management of anterior vaginal wall prolapse: an evidencebased literature review.

Authors:  Christopher Maher; Kaven Baessler
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2005-05-25

3.  Rectocele repair: a randomized trial of three surgical techniques including graft augmentation.

Authors:  Marie Fidela R Paraiso; Matthew D Barber; Tristi W Muir; Mark D Walters
Journal:  Am J Obstet Gynecol       Date:  2006-12       Impact factor: 8.661

4.  Combined anterior trans-obturator mesh and sacrospinous ligament fixation in women with severe prolapse--a case series of 30 months follow-up.

Authors:  Tsia-Shu Lo; Kiran Ashok
Journal:  Int Urogynecol J       Date:  2010-11-04       Impact factor: 2.894

5.  Primary surgical repair of anterior vaginal prolapse: a randomised trial comparing anatomical and functional outcome between anterior colporrhaphy and trocar-guided transobturator anterior mesh.

Authors:  A Vollebregt; K Fischer; D Gietelink; C H van der Vaart
Journal:  BJOG       Date:  2011-08-22       Impact factor: 6.531

6.  Risk factors for exposure, pain, and dyspareunia after tension-free vaginal mesh procedure.

Authors:  Mariëlla I Withagen; Mark E Vierhout; Jan C Hendriks; Kirsten B Kluivers; Alfredo L Milani
Journal:  Obstet Gynecol       Date:  2011-09       Impact factor: 7.661

7.  Severe mesh complications following intravaginal slingplasty.

Authors:  Kaven Baessler; Alan D Hewson; Ralf Tunn; Bernhard Schuessler; Christopher F Maher
Journal:  Obstet Gynecol       Date:  2005-10       Impact factor: 7.661

8.  Single-incision apical and posterior mesh repair: 1-year prospective outcomes.

Authors:  James C Lukban; Jan-Paul W R Roovers; Douglas M Vandrie; Ty Erickson; Samuel Zylstra; Manish P Patel; Robert D Moore
Journal:  Int Urogynecol J       Date:  2012-03-15       Impact factor: 2.894

9.  Sacrospinous cervicocolpopexy with uterine conservation for uterovaginal prolapse in elderly women: an evolving concept.

Authors:  M Hefni; T El-Toukhy; J Bhaumik; E Katsimanis
Journal:  Am J Obstet Gynecol       Date:  2003-03       Impact factor: 8.661

10.  Vaginal repair with mesh versus colporrhaphy for prolapse: a randomised controlled trial.

Authors:  M Carey; P Higgs; J Goh; J Lim; A Leong; H Krause; A Cornish
Journal:  BJOG       Date:  2009-07-07       Impact factor: 6.531

View more
  14 in total

1.  Where to for pelvic organ prolapse treatment after the FDA pronouncements? Comment.

Authors:  H M P Pelikan
Journal:  Int Urogynecol J       Date:  2013-11       Impact factor: 2.894

2.  Where to for pelvic organ prolapse treatment after the FDA pronouncements? Reply to Pelikan.

Authors:  J M van Geelen; P L Dwyer
Journal:  Int Urogynecol J       Date:  2013-11       Impact factor: 2.894

Review 3.  [Complications after rectal prolapse surgery].

Authors:  T H K Schiedeck
Journal:  Chirurg       Date:  2015-08       Impact factor: 0.955

4.  Systematic reviews of apical prolapse surgery: are we being misled down a dangerous path?

Authors:  Michael Moen; John Gebhart; Karl Tamussino
Journal:  Int Urogynecol J       Date:  2015-05-12       Impact factor: 2.894

5.  Pelvic organ prolapse surgical management in Portugal and FDA safety communication have an impact on vaginal mesh.

Authors:  Teresa Mascarenhas; Miguel Mascarenhas-Saraiva; Amélia Ricon-Ferraz; Paula Nogueira; Fernando Lopes; Alberto Freitas
Journal:  Int Urogynecol J       Date:  2014-08-16       Impact factor: 2.894

6.  Joint report on terminology for surgical procedures to treat pelvic organ prolapse.

Authors: 
Journal:  Int Urogynecol J       Date:  2020-03       Impact factor: 2.894

7.  A randomized controlled trial comparing anatomical and functional outcome between vaginal colposuspension and transvaginal mesh.

Authors:  G Lamblin; A Van-Nieuwenhuyse; P Chabert; K Lebail-Carval; S Moret; G Mellier
Journal:  Int Urogynecol J       Date:  2014-02-27       Impact factor: 2.894

8.  Effectiveness of Hyalobarrier and Seprafilm to prevent polypropylene mesh shrinkage: a macroscopic and histological experimental study.

Authors:  Erdogan Nohuz; Maher Alaboud; Claude Darcha; Abdelkrim Alloui; Bruno Aublet-Cuvelier; Bernard Jacquetin
Journal:  Int Urogynecol J       Date:  2014-03-06       Impact factor: 2.894

Review 9.  Meshy business: MRI and ultrasound evaluation of pelvic floor mesh and slings.

Authors:  Roopa Ram; Kedar Jambhekar; Phyllis Glanc; Ari Steiner; Alison D Sheridan; Hina Arif-Tiwari; Suzanne L Palmer; Gaurav Khatri
Journal:  Abdom Radiol (NY)       Date:  2021-04

10.  Can we still have a clear conscience, routinely offering vaginal mesh operations in plastic and reconstructive surgery of the pelvic organ prolapse?

Authors:  Angelika Larbig; Rudy Leon de Wilde
Journal:  GMS Interdiscip Plast Reconstr Surg DGPW       Date:  2014-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.